Search clinical trials for: PD(L)-1 inhibitor

Total 5363 results

Institute of Hematology & Blood Diseases Hospital

Recruiting

PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma

Refractory Hodgkin Lymphoma | Relapse | Hodgkin Lymphoma, Adult

China
Hunan Cancer Hospital

Recruiting

Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma

Chemotherapy Effect | NK/T-cell Lymphoma of Nasal Cavity | Immune Checkpoint Inhibitor | Epigenetic Disorder

China
Themis Bioscience GmbH
Assign Data Management and Biostatistics GmbH; Optimapharm

Withdrawn

A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract

Gastrointestinal Cancer

Germany
Sichuan University
Afﬁliated Hospital of North Sichuan Medical College; Affiliated Hospital of...

Completed

Effect of Lactulose and/or Polyethylene Glycol Solution for Bowel Preparation for Colonscopy Procedures

Colonoscopy

China
XIANG YANQUN

Recruiting

PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | T2-3N0 or T1-2N1 | EBV-DNA≤4000 Copy/ml

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors (IUNU-RC)

Non-clear Renal Cell Carcinoma

China
Shanghai Zhongshan Hospital

Unknown

SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma (SHR-1210)

Hepatocellular Carcinoma

China
Shanghai Zhongshan Hospital

Unknown

SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery

Hepatocellular Carcinoma

China
Affiliated Hospital of Nantong University

Recruiting

PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC

Esophageal Squamous Cell Carcinoma

China
Beijing Friendship Hospital
Peking University First Hospital; Peking University People's Hospital; Peking... and other collaborators

Recruiting

Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer (POLAR-STAR)

Locally Advanced Rectal Cancer

China
Dong Wang

Unknown

Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC

Non-squamous Non-small Cell Lung Cancer

China
University of Nottingham

Completed

Dehydroepiandrosterone (DHEA) Intervention To Treat Ovarian Aging (DITTO)

Infertility | Ovarian Aging | Diminished Ovarian Reserve (DOR) | Predicted Poor-responders

United Kingdom
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)

Alveolar Soft Part Sarcoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
First Affiliated Hospital of Jinan University; Shenzhen University General...

Recruiting

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Carcinoma | Digestive System Neoplasms | Intrahepatic Cholangiocarcinoma | First-line Treatment | PD-1 Inhibitor

China
The First Hospital of Jilin University

Recruiting

Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract Carcinoma (LEADER-001)

Biliary Tract Cancer

China
Icahn School of Medicine at Mount Sinai

Recruiting

Pembrolizumab for Advanced NSCLC and PS 2-3

Non-Small Cell Lung Cancer (NSCLC)

United States
Shanghai Zhongshan Hospital

Recruiting

Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC

Hepatocellular Carcinoma

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma

Osteosarcoma

China
Agenus Inc.

Recruiting

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Melanoma | Ovarian Cancer | Prostate Cancer | Non-small-cell Lung Cancer | Endometrial Cancer | Advanced Cancer | Angiosarcoma | Fibrolamellar Carcinoma | Colorectal Cancer Without Liver Metastases

United States
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)

Peripheral T Cell Lymphoma

China
Wuhan Union Hospital, China

Recruiting

Fruquintinib in the Cross-line Treatment of Refractory mCRC

Metastatic Colorectal Cancer | Fruquintinib

China
Sichuan Cancer Hospital and Research Institute

Recruiting

TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC

Liver Diseases | Digestive System Neoplasms | Liver Neoplasms | Hepatocellular Carcinoma | Antineoplastic Agents | Molecular Mechanisms of Pharmacological Action | Protein Kinase Inhibitors | Sorafenib

China
Tianjin Medical University Cancer Institute and...

Unknown

PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC (PLTHCC)

Hepatocellular Carcinoma Non-resectable

China
Calico Life Sciences LLC
AbbVie

Recruiting

A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors

Advanced Solid Tumor Cancer

United States, Korea, Republic of, Spain, Israel, Japan, France
Hunan Cancer Hospital

Completed

Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer

Metastatic Colorectal Adenocarcinoma

China
Shanghai Henlius Biotech

Recruiting

A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer

Gastric Cancer

China
Guangxi Medical University

Unknown

RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC)

Hepatocellular Carcinoma
Sidney Kimmel Cancer Center at Thomas Jefferson...
United States Department of Defense

Active, not recruiting

Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer

Colorectal Adenoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage 0 Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal... and other conditions

United States
Dana-Farber Cancer Institute

Completed

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Solid Tumors | KRAS Mutant Non-Small Cell Lung Cancer

United States
Sichuan University

Not yet recruiting

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Solid Tumor
Grit Biotechnology

Not yet recruiting

Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Squamous Cell Carcinoma

HNSCC | Adults

China
The First Affiliated Hospital of Soochow University

Recruiting

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

Relapsed/Refractory Peripheral T-cell Lymphoma

China
Medical University of Warsaw
Polish Academy of Sciences; University of Warsaw

Completed

The Effect of Bicarbonate Profiling in Dialysis Fluid on Phosphate Removal During Hemodialysis and Blood pH

Phosphorus Metabolism Disorders | Acid-Base Balance Disorder

Poland
MultiVir, Inc.

Unknown

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Lymphoma | Solid Tumor

United States
Melanoma Institute Australia
Merck Sharp & Dohme LLC

Not yet recruiting

Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma (Neo PeLeMM)

Mucosal Melanoma

Australia
University of British Columbia

Withdrawn

PDE5i Use in Renal Transplant Recipients

Renal Transplant Failure

Canada
Guoxin Li

Not yet recruiting

Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer（RC48-C018）

Gastric Cancer
Hunan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | Squamous Cell Carcinoma

China
Dynavax Technologies Corporation

Completed

Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC

Advanced Non Small Cell Lung Cancer

United States
Chinese PLA General Hospital

Completed

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer

Ovarian Cancer

China
Hunan Cancer Hospital

Completed

Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer

Colorectal Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC

Head and Neck Cancer

China
Leiden University Medical Center
Radboud University Medical Center; AstraZeneca; University Medical Center Groningen and other collaborators

Active, not recruiting

Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer (DOMEC)

Uterine Neoplasms | Endometrial Neoplasms | Endometrium Cancer

Netherlands
Emory University
National Cancer Institute (NCI)

Withdrawn

Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases

Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Breast Carcinoma | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
Li Xiao Wei

Not yet recruiting

HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL) (HAI-TL)

Hepatocellular Carcinoma With PVTT

China
Sun Yat-sen University
Guangdong Provincial Hospital of Traditional Chinese Medicine; Fujian Cancer... and other collaborators

Recruiting

PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients

Lynch Syndrome

China
RenJi Hospital

Completed

Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma

Neoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial Carcinoma

China
Symphogen A/S

Completed

Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Lymphoma | Solid Tumor | Metastatic Cancer

Canada, United States
Sun Yat-sen University
Guangzhou No.12 People's Hospital; Kaiping Central Hospital

Withdrawn

HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC

Hepatocellular Carcinoma

China
Shi Ming

Suspended

Lenvatinib Plus PD-1 Antibody for Unresectable ICC

Intrahepatic Cholangiocarcinoma

China

Search clinical trials for: PD(L)-1 inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations